From: Applicability of polygenic risk scores in endometriosis clinical presentation
Crude OR (95% CI) | p-value | Adj. OR (95% CI) | p-value | |||
---|---|---|---|---|---|---|
Isolated/spread | Isolated/spread | p-value | ||||
Quartile 1 | 10/23 | 0.111 | 1.000 | 1.000 | ||
Quartile 2 | 15/18 | 0.522 (0.190–1.433) | 0.207 | 0.496 (0.154–1.599) | 0.240 | |
Quartile 3 | 20/16 | 0.348 (0.129–0.938) | 0.037 | 0.252 (0.081–0.782) | 0.017 | |
Quartile 4 | 11/23 | 0.909 (0.324–2.554) | 0.857 | 0.616 (0.192–1.974) | 0.415 | |
P for trend | 0.243 | |||||
No GI tract involvement /GI tract involvement | No GI tract involvement /GI tract involvement | P-value | ||||
Quartile 1 | 26/7 | 0.144 | 1.000 | 1.000 | ||
Quartile 2 | 30/3 | 0.371 (0.087–1.581) | 0.181 | 0.158 (0.026–0.949) | 0.044 | |
Quartile 3 | 28/8 | 1.101 (0.349–3.470) | 0.870 | 0.950 (0.248–3.644) | 0.940 | |
Quartile 4 | 23/11 | 1.1776 (0.591–5.343) | 0.306 | 1.962 (0.524–7.338) | 0.317 | |
P for trend | 0.100 | |||||
No GI symptoms/ GI symptoms | No GI-symptoms/ GI-symptoms | P-value | ||||
Quartile 1 | 5/30 | 0.631 | 1.000 | 1.000 | ||
Quartile 2 | 3/29 | 1.611 (0.352–7.364) | 0.538 | 4.219 (0.509–34.978) | 0.182 | |
Quartile 3 | 7/29 | 0.690 (0.197–2.425) | 0.563 | 0.317 (0.065–1.539) | 0.154 | |
Quartile 4 | 7/28 | 0.667 (0.190–2.345) | 0.528 | 0.530 (0.102–2.761) | 0.451 | |
P for trend | 0.138 | |||||
No hormone therapy /hormone therapy | No hormone therapy /hormone therapy | P-value | ||||
Quartile 1 | 18/17 | 0.902 | 1.000 | 1.000 | ||
Quartile 2 | 18/16 | 0.941 (0.366–2.421) | 0.900 | 1.052 (0.344–3.213) | 0.930 | |
Quartile 3 | 20/16 | 0.847 (0.333–2.155) | 0.727 | 0.713 (0.243–2.087) | 0.537 | |
Quartile 4 | 21/14 | 0.706 (0.274–1.820) | 0.471 | 0.613 (0.205–1.830) | 0.380 | |
P for trend | 0.285 |